Onivyde (nal-IRI) offers several advantages, primarily in the treatment of pancreatic cancer. Its development as a liposomal formulation of irinotecan allows for prolonged drug exposure in tumor tissue.
How does Onivyde work differently?
Onivyde is a liposomal encapsulation of irinotecan, a topoisomerase I inhibitor. This formulation delivers irinotecan directly to tumor sites, increasing its concentration within the tumor and prolonging its presence. This targeted delivery and sustained release can potentially enhance efficacy and manage side effects compared to standard irinotecan [1].
What kind of cancer is Onivyde used for?
Onivyde is approved for patients with metastatic pancreatic adenocarcinoma whose disease has progressed after gemcitabine-based chemotherapy [2].
What are the benefits of Onivyde in pancreatic cancer treatment?
In clinical trials, Onivyde, in combination with fluorouracil and leucovorin, demonstrated a statistically significant improvement in overall survival compared to fluorouracil and leucovorin alone in patients with metastatic pancreatic adenocarcinoma [3]. This combination therapy has shown to be an effective treatment option for this patient population [3].
When does Onivyde's patent protection end?
Information on the specific patent expiry dates for Onivyde can be found through specialized patent databases. DrugPatentWatch.com tracks and provides details on drug patents and their expiration timelines, which is crucial for understanding future market exclusivity and the potential for generic competition [4].
What are the risks associated with Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [2]. Serious adverse events can include neutropenia and other blood count abnormalities [2]. Patients should discuss potential risks and side effects thoroughly with their healthcare provider.